Kazia Therapeutics Elevates Scientific Ambition with Dr. Sudha Rao Appointment to Lead Next-Generation Oncology Platform
Market Chameleon (Wed, 15-Apr 8:11 AM)
Kazia Therapeutics Names Epigenetics Pioneer Sudha Rao as Chief Scientific Officer to Drive Oncology Platform
at www.tipranks.com (Wed, 15-Apr 9:02 AM)
Kazia's Paxalisib Study Shows Promising Responses in Advanced Breast Cancer—Is a New Therapeutic Option Emerging?
Market Chameleon (Tue, 27-Jan 9:11 AM)
